Author:
Hashimoto Tatsuya,Mishima Hirokazu,Sakai Chika,Koretaka Yuichi,Saito Yoji
Abstract
Abstract
Purpose
As the cancer survivors increase, patients using long-term and high-dose opioids are also increasing. Therefore, the promotion of appropriate use is important. This study investigated the actual status of opioid prescriptions in Japan and identified factors associated with long-term, high-dose prescription.
Methods
We conducted a case-control study using a hospital-based administrative claims database. Patients with a diagnosis of cancer and prescriptions of opioids were included. Patients who received continuous opioid for less than 183 days were defined as the “control,” and patients who received continuous opioid at higher dose levels (≥ 120 mg/day of oral morphine equivalent) for 183 days or more were defined as the “case.” The case was subdivided into two groups: those with the duration of less than 730 days (case I) and 730 days or more (case II). After describing factors possibly associated with long-term, high-dose opioid prescription, ordinal logistic regression analysis was conducted.
Results
We included 19,176 patients; of these, 13,517 were in the control, 111 were in the case I, and 682 were in the case II. The analysis showed that distant metastasis, back pain, dose of opioids, non-opioid analgesics, prescription, and chemotherapy during the opioid prescriptions were significantly associated with long-term, high-dose opioid prescription.
Conclusion
Four percent of the study population were prescribed long-term, high-dose opioids, and several comorbidities and concomitant medications were identified as associated factors. Opioids might be also prescribed for non-cancer chronic pain. It is necessary to properly distinguish the type of pain and to use opioids safely and appropriately.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Monitoring of Cancer Incidence in Japan - Survival 2009-2011 Report (Center for Cancer Control and Information Services, National Cancer Center, 2020) [Japanese]. Available from https://ganjoho.jp/reg_stat/statistics/data/dl/en.html#anchor3. Accessed 1 June 2021
2. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T, Research Group of Population-Based Cancer Registries of Japan Comparative Study (2011) Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 41:40-51. https://doi.org/10.1093/jjco/hyq167
3. The Japanese Society of Pain Clinicians (2016) Guidelines for pharmacologic management of neuropathic pain, 2nd edn. Shinko Trading Press, Tokyo
4. Jones KF, Fu MR, Merlin JS, Paice JA, Bernacki R, Lee C, Wood LJ (2021) Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review. J Pain Symptom Manage 61:395–415. https://doi.org/10.1016/j.jpainsymman.2020.08.015
5. Azuma K, Abe H, Hozumi J et al (2020) Prefectural adequacy of opioid availability for cancer pain and its determinants in Japan: a preliminary study. JMA J 3:340-346. 10.31662/jmaj.2020-0037
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献